ABUS vs PEAK
Arbutus Biopharma Corp (ABUS) versus PEAK (PEAK) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
PEAK (PEAK) common stock.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
PEAK does not have a complete income-statement cache yet.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Not investment advice. Open the ABUS and PEAK stock pages for the full models.
Not investment advice.